haematology
Blood cancers

It won’t happen overnight… but response to ibrutinib better in treatment naïve

While not available in Australia as a first line treatment for chronic lymphocytic leukaemia (CLL) or small lymphocytic leukaemia (SLL), ibrutinib has been shown to be more effective in achieving complete response when given before other treatments. The study, which pooled data from trials PCYC-1102 and PCYC-1112, found the odds of achieving complete response were ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic